April 16th 2024
During a Case-Based Roundtable® event, Madappa Kundranda, MD, PhD, discussed recent retrospective studies that compared outcomes between the available treatment options in patients with relapsed/refractory advanced colorectal cancer in the first article of a 2-part series.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Bevacizumab and Chemotherapy Remains Standard of Care in RAS/RAF Mutated mCRC
August 4th 2022In an interview with Targeted Oncology, Christopher Nevala-Plagemann, MD, discussed the key takeaways of his research on the best treatment strategies for patients with left sided RAS or RAF wild-type metastatic colorectal cancer.
Read More
Trials Lead to Change in Prescription Patterns for Older Adults With Colorectal Cancer
July 22nd 2022The phase 3 CALGB 9343 study significantly changed prescription patterns for patients with metastatic colorectal cancer, according to a presentation at the International Society for Pharmacoeconomics and Outcomes Research 2022.
Read More
Atezolizumab Increases PFS in Front-Line FOLFIXIR Plus Bevacizumab Treatment in Patients with mCRC
June 22nd 2022Adding atezolizumab to first-line FOLFOXIRI with bevacizumab is shown to be a safe treatment option and improves progression-free survival in patients with metastatic colorectal cancer.
Read More
FOLFOXIRI Plus Bevacizumab Shows Positive Efficacy But Increased Toxicity in CRC Liver Metastases
June 7th 2022Phase 3 CAIRO5 showed improvements in progression-free survival and overall response with FOLFOXIRI plus bevacizumab in colorectal cancer liver metastases, but the combination demonstrated a toxic safety profile.
Read More
Real-World Data Show More Research is Needed for Risk Stratification in Advanced Colon Cancer
April 20th 2022In an interview with Targeted Oncology, Luv Hajirawala, MD, discussed the relevance of high-risk features in patients with stage III colon cancer, and how a recent real-world analysis may change risk stratification in the future.
Read More
Colorectal Cancer Awareness Month: Overcoming Barriers to Early Detection
March 18th 2022Charles Meakin, MD, MHA, chief medical officer of Care Oncology, discusses the current colorectal cancer landscape, innovations in detection, and improving patient screening and follow-up care for Colorectal Cancer Awareness Month.
Read More
FDA Places Partial Clinical Hold on Study of CYAD-101 in mCRC
March 1st 2022Pending a safety investigation by the developer and further information about risk to patients, the phase 1b trial of CYAD-101 in patients with metastatic colorectal cancer, has been placed on a partial clinical hold by the FDA.
Read More
Roundtable Discussion: Kundranda and Participants Review First-line and Later-line Therapies in CRC
February 1st 2022During a Targeted Oncology case-based roundtable event, Madappa Kundranda, MD, PhD, and participants discussed the case of a patient with recently diagnosed, unresectable colorectal cancer.
Read More